Carvacrol

Carvacrol: A Comprehensive Reference

1. Identity and Chemical Profile

Names and Classification

Carvacrol, also known as cymophenol and bearing the molecular formula C₆H₃(CH₃)(OH)C₃H₇, is a monoterpenoid phenol. Its systematic IUPAC name is 5-isopropyl-2-methylphenol, though it is also written as 2-methyl-5-(propan-2-yl)phenol. Carvacrol is an isomer of thymol, the other principal phenolic monoterpene found in these aromatic herbs.

Carvacrol has lipophilic properties — it is highly soluble in ethanol and acetone but insoluble in water. Its melting and boiling temperatures are 1 °C and 237–238 °C, respectively, and its refractive index falls between 1.5210 and 1.5260. It has a characteristic pungent, warm odor of oregano.

Botanical Sources

Carvacrol is a monoterpenic phenol produced by an abundant number of aromatic plants, including thyme and oregano. More specifically, carvacrol is naturally present in the essential oils of various aromatic plants, including oregano (Origanum vulgare), thyme (Thymus vulgaris), Shirazi thyme (Zataria multiflora Boiss.), ajwain (Carum copticum), pepperwort (Lepidium flavum), black cumin (Nigella sativa L.), and wild bergamot (Citrus aurantium var. bergamia). It is also found in tequila and Lippia graveolens (Mexican oregano) in the verbena family.

Carvacrol concentrations vary substantially across plant species. The essential oil of thyme subspecies contains between 5% and 75% carvacrol, while Satureja (savory) subspecies have a content between 1% and 45%. Origanum majorana (marjoram) and dittany of Crete are rich in carvacrol at 50% and 60–80%, respectively. The Lamiaceae family, one of the main families of aromatic and medicinal plants, produces significant amounts of essential oils. It is a large family that includes oregano and thyme in addition to lavender, marjoram, sage, and peppermint; they often accumulate volatile chemicals in glandular trichomes.

Common Forms and Preparations

Carvacrol is used in low concentrations as a food flavoring ingredient and preservative, as well as a fragrance ingredient in cosmetic formulations. As a supplement, it is most commonly encountered as a constituent of oregano essential oil, which is available in liquid form diluted in a carrier oil, in softgel capsules, or as an enteric-coated preparation. Pure carvacrol isolates also exist in research and industrial contexts.

Carvacrol has been approved by the FDA for use in food and listed by the Council of Europe as a Category B chemical flavoring agent that may be added to foodstuffs at a level of 2 ppm in beverages, 5 ppm in flakes, and 25 ppm in candies. Regulatory organizations such as the European Commission, the Joint FAO/WHO Committee on Food Additives (JECFA), and the Food and Drug Administration (FDA) classify carvacrol as safe, but only as a flavoring ingredient in foods.

The poor solubility and stability of carvacrol limit its application. Nanotechnology is a suitable tool to overcome these limitations; research has summarized the development of carvacrol nano-based drug delivery systems for the food and pharmaceutical industries.

2. Historical and Traditional Use

The earliest mentions of oregano and thyme date back to ancient Greek and Roman texts; Hippocrates and Dioscorides noted their digestive and antiseptic use. It was not until the 19th century that chemists isolated carvacrol itself. In 1926, Swiss researchers identified the phenolic structure, and later mid-20th century studies confirmed its bacterial inhibition in vitro. Wide clinical trials on humans only started appearing after 2000.

Traditional use, therefore, was not directed at carvacrol as an isolated compound but rather at whole plant preparations rich in it. The genus Origanum has been widely used for various purposes such as food additives and medicine in traditional medicine. Among the Lamiaceae family, the genus Origanum and Thymus are widely known and highly appreciated in traditional medicine throughout the world. In Morocco, both species are included in the most significant medicinal plants commonly used in traditional medicine and studied for their several biological activities. Known locally as "Zaâtre" for O. compactum and "Zaîtra" for T. zygis, they may be applied against a wide spectrum of pathologies and in industrial fields such as foods, pharmaceuticals, aromatherapy, and perfumes.

Across Mediterranean cuisines, oregano leaves were added to bread, meat stews, and wine — practices that unknowingly delivered carvacrol. In traditional Middle Eastern food, za'atar spice blends harness carvacrol-rich herbs. These culinary uses served implicit preservative and digestive purposes long before carvacrol's chemical identity was known. Oregano has been used for centuries as a traditional herb, spice, and in traditional medicine. Oregano essential oils have been used as ingredients in several applications including toothpaste, mouthwash, and gums; the main active molecules in oregano essential oil are carvacrol and thymol.

3. Key Constituents and Mechanisms of Action

Structural Basis of Bioactivity

Terpene chemicals are secondary metabolites that are found largely in herbs as ingredients of essential oils. There are just two terpene phenolic chemicals present in essential oils: thymol and carvacrol. Aromatic plants produce these organic compounds in part as a defense against phytopathogenic insects, bacteria, fungi, and viruses. The hydroxyl group on carvacrol's phenolic ring is central to its biological activities: carvacrol shows biological activities such as antimicrobial, antitumor, antimutagenic, antigenotoxic, anti-inflammatory, anti-angiogenic, hepatoprotective, and antihepatotoxic properties. Because of the hydroxyl groups on its phenolic ring, carvacrol reduces oxidative damage.

TRP Channel Modulation

One of the most pharmacologically significant mechanisms of carvacrol involves transient receptor potential (TRP) ion channels. Carvacrol is a potent activator of the human ion channels transient receptor potential V3 (TRPV3) and A1 (TRPA1). Patch-clamp whole-cell recordings demonstrated that carvacrol, as a known activator of the thermoTRPs TRPV3 and TRPA1, is also an inhibitor of the Drosophila TRPL channels, which belongs to the TRPC subfamily. Carvacrol, a naturally occurring bioactive monoterpenoid phenol, also possesses non-specific inhibitory properties against TRPM7. TRPV3 channels are found in keratinocytes and neurons, and their activation by carvacrol is relevant to both skin sensation and pain modulation. TRPA1 activation is relevant to cough and pain signaling pathways.

Antimicrobial Mechanisms

Carvacrol is a hydrophobic monoterpene in nature that easily penetrates the cell membranes of bacteria, leading to disruption of cell membrane integrity as well as release of bacterial cell contents. In Gram-negative bacteria, carvacrol depolarizes the cytoplasmic membranes. Furthermore, carvacrol appears to affect ATP synthesis and subsequently reduces other energy-dependent cellular processes such as the synthesis of enzymes and toxins. The mechanism of action involves compromising cell membrane integrity; carvacrol induced membrane integrity changes leading to leakage of cytoplasmic content such as lactate dehydrogenase enzymes and nucleic acids.

These pathways influence membrane homeostasis and proton motive force (PMF), supporting previous studies stating that membrane disruption and depolarization underlie carvacrol antibacterial activity.

Anti-Inflammatory Mechanisms

Carvacrol reduces inflammatory biomarkers such as nuclear factor κB (NF-κB) and cyclooxygenase-2 (COX-2), and reduces levels of nitric oxides, malondialdehyde, and glutathione involved in oxidative stress. Carvacrol exerts anti-inflammatory properties by preventing the peroxidation of polyunsaturated fatty acids by inducing SOD, GPx, GR, and CAT, as well as reducing the level of pro-inflammatory cytokines in the body. It also affects the body's immune response generated by LPS.

Antifungal Mechanisms

Carvacrol impairs the cell membrane and endoplasmic reticulum (ER) by disrupting ergosterol biosynthesis. Although the definitive antifungal mechanism of carvacrol remains unclear, its toxicity has been linked to the disruption of the cell membrane, ergosterol production, endoplasmic reticulum stress, and H⁺ and Ca²⁺ dyshomeostasis.

Anticancer Mechanisms

Carvacrol has anticancer ability against malignant cells via decreasing the expressions of matrix metalloprotease 2 and 9, inducing apoptosis, enhancing the expression of pro-apoptotic proteins, disrupting mitochondrial membrane, suppressing extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signal transduction, and also decreasing the phosphoinositide 3-kinase/protein kinase B. Carvacrol affects cell survival and cell-killing activity by targeting key biomarkers and major signaling pathways, including PI3K/AKT/mTOR, MAPK, STAT3, and Notch.

4. Scientific Evidence by Area of Use

4.1 Antimicrobial Activity

The antimicrobial properties of carvacrol are among its best-investigated biological activities. Carvacrol, either alone or in combination with other compounds, has a strong antimicrobial effect on many different strains of bacteria and fungi that are dangerous to humans or can cause significant losses in the economy. Carvacrol has been found to exert antimicrobial activity against Staphylococcus aureus, Pseudomonas aeruginosa, coagulase-negative staphylococcus, Salmonella spp., Enterococcus sp., Shigella, and Escherichia coli.

Specific in-vitro studies have quantified minimum inhibitory concentrations (MICs). One study determined the antimicrobial potential of carvacrol against ESBL Escherichia coli isolated from ascitic fluid of a patient having a urinary tract infection. Carvacrol exhibited a minimum inhibitory concentration (MIC) of 450 μg/mL, at which it reduced E. coli cell counts significantly in a time-dependent manner, and completely diminished the growth of E. coli after 2 hours of incubation at its MIC. The MIC and minimum bactericidal concentration (MBC) of carvacrol against S. pyogenes were 125 µg/mL (0.53 mM) and 250 µg/mL (1.05 mM), respectively; kill-curve results showed that carvacrol exhibits instantaneous bactericidal activity against S. pyogenes.

Evidence also exists for anti-biofilm activity. Carvacrol reduced the hydrophobic properties of multicellular bacterial structures by up to 84.2%, and was able to reduce the expression of the LuxS gene associated with the formation of biofilms by S. pyogenes.

Research on Campylobacter jejuni, a major foodborne pathogen, showed that subinhibitory concentrations of carvacrol inhibited the motility of C. jejuni without affecting bacterial growth; immunoblotting and electron microscopy showed that carvacrol-treated C. jejuni still expressed flagella. In vitro infection assays demonstrated that subinhibitory concentrations of carvacrol also abolished C. jejuni invasion of human epithelial cells.

Evidence strength: Antimicrobial activity is strongly established in vitro across a broad range of human pathogens, including antibiotic-resistant strains. However, most evidence remains preclinical (in vitro and animal). No large-scale, controlled clinical trials have yet confirmed these effects in treating human bacterial infections with carvacrol as a standalone therapeutic agent.

4.2 Antifungal Activity

Carvacrol, a phenolic monoterpenoid, exhibits low MICs against fungi and has a broad spectrum of antifungal activity. Moreover, carvacrol has low cytotoxicity and is effective in the treatment of systemic candidiasis with C. albicans and non-C. albicans (C. krusei and tropicalis) in mouse models, making it a promising potential natural antifungal against candidal infections for clinical use.

Research confirmed the antifungal activity of carvacrol against C. albicans, C. glabrata, C. krusei, and C. dubliniensis from MIC 161.3 mg/L. Research on the pathogenic Candida auris strain showed that the growth of all C. auris isolates was inhibited by carvacrol in the MIC range of 125–500 μg/mL, and the MFC values for the same isolates were in the range of 250–1000 μg/mL.

A more recent study examined carvacrol against emerging fungal pathogens: carvacrol inhibited adherence and significantly reduced both early and preformed biofilms in M. guilliermondii and C. dubliniensis. In C. auris, the compound produced a modest reduction in biofilm activity but significantly enhanced larval survival in the in vivo model (~20%, p < 0.01). Carvacrol exhibits species-specific effects, acting as an antivirulence modulator in M. guilliermondii and C. dubliniensis and attenuating virulence in vivo in C. auris. These findings support the potential of carvacrol as an adjuvant antifungal strategy.

Evidence strength: Antifungal evidence is well established in vitro and in animal models, with mechanistic data. No human clinical trials for fungal infections using carvacrol as the primary therapeutic agent have been published; evidence remains preclinical.

4.3 Anti-Inflammatory and Antioxidant Activity

Anti-inflammatory and antioxidant effects represent another well-studied dimension of carvacrol's bioactivity. It possesses pharmacological activities, including anticancer, anti-genotoxic, and anti-inflammation associated with antioxidant properties. Reviews of available studies reveal that carvacrol inhibits acetylcholinesterase (AChE) activity and alters lipid profiles, reducing heart rate as well as systolic and diastolic blood pressure. Carvacrol also decreased the proinflammatory cytokine IL-1β, while increasing secretion of anti-inflammatory cytokine IL-10. Moreover, carvacrol improved oxidative stress and mitigated the number of apoptotic cells.

In a study using human tonsil epithelial cells, carvacrol suppressed inflammatory biomarker production stimulated by lipoteichoic acid and peptidoglycan, providing evidence at the cellular level relevant to human tissue. Carvacrol administration also increased the number of CD4⁺CD25⁺FoxP3⁺ T cells, both systemically in the spleen and locally in the joint, and almost completely suppressed experimental proteoglycan-induced arthritis in animal models.

Evidence strength: Robust preclinical (cellular and animal model) data. Mechanistic pathways — particularly NF-κB inhibition, COX-2 suppression, and reactive oxygen species scavenging — are well characterized. Human clinical trial data specific to carvacrol's anti-inflammatory effects remain limited.

4.4 Cardiovascular Effects

The pharmacological effects of carvacrol on cardiovascular disease (CVD) may be through its antioxidative, anti-inflammatory, and antiapoptotic effects. The therapeutic effects of carvacrol on lipid profile, hypertension, and cardiac dysfunction indicate the possible remedy effect of carvacrol for the treatment of CVD. Previous research has linked dietary consumption of carvacrol to a lower risk of cardiovascular disease.

Carvacrol also decreased the concentrations of alanine aminotransferase, alkaline phosphatase and aspartate aminotransferase, and gamma-glutamyl transpeptidase, and restored liver function, insulin level, and plasma glucose level in preclinical studies. These hepatic parameters have indirect relevance to metabolic cardiovascular risk.

At the ion-channel level, despite the wide application of carvacrol in medicines, dietary supplements, and foods, there is still insufficient electrophysiological data on the mechanisms of action of carvacrol with regard to heart function. Studies have attempted to elucidate whether carvacrol, whose inhibitory effect on both cardiac and vascular TRPM7 and L-type Ca²⁺ currents has been demonstrated, could modify cardiac electrical activity.

Evidence strength: Primarily animal and in-vitro evidence with mechanistic plausibility. No controlled human clinical trials have specifically examined carvacrol's cardiovascular outcomes. The observed effects on lipid profiles, blood pressure, and cardiac function remain to be confirmed in humans.

4.5 Anticancer Activity

Carvacrol has attracted considerable interest as a potential anticancer agent, though all evidence to date is preclinical. A 2021 systematic review identified a total of 1,170 records, with 77 meeting established criteria for inclusion. The studies were published between 2003 and 2021, with 69 being in vitro and 10 in vivo. Forty-three used carvacrol, 19 thymol, and 15 studies tested both monoterpenes.

Carvacrol depicts ROS-dependent and mitochondrial-mediated apoptosis in different cancer cells. Moreover, carvacrol significantly regulates the cell cycle and prevents tumor progression. Some reports also suggest its significant role in inhibiting cell migration, invasion, and angiogenesis in tumor cells.

In breast cancer models, carvacrol (0, 100, 150, and 200 μM) inhibited cell development and induced apoptosis in doxorubicin-resistant MDA-MB-231 breast cancer cells via cell cycle arrest at S and G2/M phases, enhanced Bax expression, while reducing Bcl-2, PI3K, and P-AKT expression. In hepatocellular carcinoma models, an in vitro analysis showed that carvacrol (45 μg/mL) and essential oil (0.08 μg/mL) of Origanum onites altered the expression of 48 genes out of 84 in HepG2 cells; these 48 genes are associated with hepatocellular carcinoma and inflammatory pathways.

Until now, the anticancer mechanism is not yet fully explored. A limited number of research studies have been conducted on carvacrol. It possesses both cancer prevention and cancer therapeutic properties, but this molecule needs more validatory research so that it can be analyzed precisely.

Evidence strength: Preliminary, confined entirely to in vitro and animal models. No human clinical trials examining carvacrol as a cancer therapy or chemopreventive agent exist. Results are promising but require substantial further investigation before any clinical conclusions can be drawn.

4.6 Respiratory and Allergic Disorders

Carvacrol has shown various pharmacological and therapeutic effects in different disorders. Experimental and clinical effects of carvacrol on respiratory, allergic, and immunologic disorders have been described in the literature. Carvacrol showed a relaxant effect, with various possible mechanisms suggesting the bronchodilatory effect in obstructive pulmonary diseases.

One Phase I clinical trial specifically addressed respiratory parameters: treatment with carvacrol 2 mg/kg/day for one month increased FEV1 (p < 0.05). This single small study provides a direct measurement of a respiratory outcome in humans, but results must be interpreted cautiously given the study's limited size and primary safety focus.

Evidence strength: A small body of clinical evidence from a Phase I safety trial that incidentally observed changes in spirometry. Animal and mechanistic evidence supports bronchodilatory effects, but dedicated clinical trials for respiratory conditions are lacking.

4.7 Neuroprotective Effects

Carvacrol is able to cross the blood-brain barrier easily, notably improving its therapeutic efficacy in neurodegenerative disorders. The data from experimental studies show that carvacrol reduces the manifestations of cognitive impairments, motor dysfunctions, oxidative stress, inflammation, and death of neuronal cells, which is indicative of its multi-targeted preventive potential.

In Alzheimer's disease models, carvacrol has a potent therapeutic impact in lowering the aggregation and accumulation of amyloid-beta (Aβ), which is one of the classical pathological features of Alzheimer's disease. In rodent behavioral models, carvacrol (25 mg/kg, oral) confers antidepressant and neuroprotective effects, possibly by normalizing the dopaminergic brain pathway in forced swim test (FST) and tail suspension test (TST) models. After oral administration for one week, carvacrol (12.5 mg/kg) increases 5-HT and dopamine levels in hippocampus and prefrontal cortex in FST of rats.

The available experimental studies have demonstrated that carvacrol has the potential to be a neuroprotective agent against Alzheimer's and Parkinson's diseases. The data from experimental studies show that carvacrol reduces the manifestations of cognitive impairments, motor dysfunctions, oxidative stress, inflammation, and death of neuronal cells.

Evidence strength: Entirely preclinical — in vitro and animal model data only. No human clinical trials for neurodegenerative or neuropsychiatric conditions have been published. The ability to cross the blood-brain barrier, confirmed in animal models, is a promising pharmacokinetic property that lends biological plausibility.

4.8 Gastrointestinal Effects

Carvacrol has been studied for its effects on gastrointestinal pathogens and intestinal ecology. Research has explored carvacrol as a Clostridium difficile therapeutic agent due to its inhibitory effect on C. difficile toxin production without affecting the growth of beneficial gut bacteria in vitro. This study demonstrated that carvacrol significantly inhibited toxin production in hypervirulent C. difficile strains by modulating toxin production genes.

Evidence strength: Primarily in vitro and animal model data. The selectivity against pathogens relative to beneficial gut bacteria is a notable finding, but human clinical studies in this area remain absent.

5. Pharmacokinetics and Bioavailability

In rabbits, 1.5 g of orally administered carvacrol is progressively absorbed from the intestines, with approximately 30% of the whole dose remaining in the gastrointestinal system and 25% eliminated via urine after 22 hours of administration. When carvacrol in sesame oil was given to rats (500 mg) and rabbits (1,500 and 5,000 mg) via gavage, it was found to be distributed in the intestines, stomach, and urine, with tiny levels in muscle, liver, and lung.

More than 80% of carvacrol is absorbed or metabolized in the gastrointestinal tract following oral administration, as reported in metabolic studies. Regarding the wider use of carvacrol as an antimicrobial agent, its bioavailability is a major limitation. For therapeutic applications, the poor solubility and stability of carvacrol limit its application, and nanotechnology is being explored as a tool to overcome these limitations.

6. Dosage Forms and Dosages Reported in Studies

Dosages used in published research vary widely depending on the condition studied, the model used, and the route of administration. The following are dosages as explicitly stated in cited sources:

• Phase I human safety trial: Healthy subjects were randomly divided into two groups receiving 1 mg/kg/day and 2 mg/kg/day of carvacrol for one month.
• Animal neuropsychiatric models (rodent): Carvacrol at 25 mg/kg oral administration confers antidepressant and neuroprotective effects in FST and TST mouse models.
• Animal serotonin/dopamine study (rat): Carvacrol 12.5 mg/kg oral for one week increased 5-HT and dopamine levels in the hippocampus and prefrontal cortex.
• In vitro breast cancer: Carvacrol at 0, 100, 150, and 200 μM concentrations were studied for effects on doxorubicin-resistant MDA-MB-231 cells.
• In vitro antibacterial (ESBL E. coli): An MIC of 450 μg/mL was established.
• In vitro against S. pyogenes: MIC of 125 µg/mL (0.53 mM) and MBC of 250 µg/mL (1.05 mM).
• In vitro against Candida auris: Growth of all C. auris isolates was inhibited in MIC range of 125–500 μg/mL; MFC values were in the range of 250–1000 μg/mL.

No standardized therapeutic dosage for carvacrol as a supplement has been established in human clinical guidelines as of the current evidence base.

7. Safety Considerations

Regulatory Status

The U.S. Food and Drug Administration classifies carvacrol as Generally Recognized as Safe (GRAS) for use as a flavoring agent in food, listed under regulation 21 CFR 172.515. This means it has a long history of safe consumption at the levels typically found in food and seasoning. GRAS status applies to carvacrol as a food flavoring, not as a high-dose supplement. Concentrated oregano oil products can contain far more carvacrol than would be obtained from cooking with oregano, and the safety profile at supplemental doses is less well established.

Human Phase I Clinical Evidence

In a Phase I clinical trial, carvacrol was administered to healthy subjects at 1 and 2 mg/kg/day for 1 month, and no critical adverse reactions or clinically significant changes in biochemical, hematological, endocrine, renal, or hepatic function tests were observed. However, specific subgroup changes were noted within the normal range. In the group receiving 1 mg/kg/day carvacrol, calcium, erythrocyte sedimentation rate (ESR), mean cell volume (MCV), hemoglobin (Hb), and hematocrit (HCT) levels were significantly reduced but creatinine phosphokinase (CPK) was significantly increased after treatment compared to baseline values. There was significant reduction in HDL cholesterol, total bilirubin, amylase, iron, red blood cell count, and HCT after one-month treatment with 2 mg/kg/day carvacrol compared to pretreatment values; however, all post-treatment measured parameters were within the normal range. The results of this Phase I study regarding carvacrol effects on healthy subjects showed clinical safety and tolerability for this agent.

Animal Toxicology Data

In studies using rats as an experimental model, carvacrol was found to be safe at doses lower than 50 mg/kg body weight, with no adverse effects reported. At very high doses by injection, more serious effects were observed: within the first 2 days of carvacrol treatment at intramuscular injection doses of 300–500 mg/kg body weight, one male mouse died in each dose level. Among examined parameters, significantly higher relative kidney weights were observed in the 300 mg/kg carvacrol group (p < 0.001). These findings are at extreme doses via a non-oral route and are not directly translatable to supplement or food use.

Mucosal Irritation

The compound can irritate mucous membranes in concentrated form, which is relevant when encountering oregano oil capsules or liquid extracts.

Genotoxicity Assessment

Several studies have assessed carvacrol's safety profile, emphasizing its low toxicity and selective effect on malignant and pathogenic cells while sparing healthy tissues. An in vivo genotoxic study with doses ranging from 81 to 810 mg/kg body weight found no signs of genotoxicity. Carvacrol possesses weak mutagenic and genotoxic potential at non-toxic doses.

Metabolic Limitations and Data Gaps

Carvacrol is considered a safe compound despite the limited amount of data on its metabolism in humans. Carvacrol is generally considered to be a safe compound. Therefore, the lack of detailed data on its metabolism in humans is surprising. The absence of comprehensive human pharmacokinetic and drug-interaction data represents a notable evidence gap for use of high-dose supplemental preparations.

8. Body Systems and Health Areas Associated with Carvacrol

• Immune/Infectious Disease: Broad-spectrum antibacterial and antifungal activity; anti-biofilm effects; modulation of immune cell populations.
• Gastrointestinal: Activity against foodborne pathogens and C. difficile; effects on gut microbiome selectivity in animal models.
• Respiratory: Bronchodilatory effects demonstrated in animal models and one Phase I trial (FEV1 increase at 2 mg/kg/day).
• Cardiovascular: Blood pressure reduction, lipid profile modulation, and cardiac protection in animal models; TRPM7 and L-type Ca²⁺ channel interaction.
• Neurological: Neuroprotection, acetylcholinesterase inhibition, dopamine and serotonin modulation; amyloid-beta reduction in AD models.
• Oncology: Apoptosis induction, cell cycle arrest, anti-angiogenic, and anti-metastatic properties in cell lines and animal models.
• Skin/Sensory: TRPV3 and TRPA1 activation, relevant to pain and sensory signal modulation.
• Metabolic/Hepatic: Lipid-lowering effects, hepatoprotective activity, and glycemic-related enzyme modulation observed in animals.

References

• Suntres ZE, et al. "The bioactivity and toxicological actions of carvacrol." Critical Reviews in Food Science and Nutrition (2015). PubMed PMID 24915411.
• Bhatt S, et al. "Chemistry and multibeneficial bioactivities of carvacrol (4-isopropyl-2-methylphenol), a component of essential oils produced by aromatic plants and spices." Journal of Agricultural and Food Chemistry (2014). PubMed PMID 25058878.
• Mączka W, et al. "Carvacrol — A Natural Phenolic Compound with Antimicrobial Properties." Molecules (2023). PMC10215463.
• Khazdair MR, et al. "Protective effects of carvacrol on lipid profiles, oxidative stress, hypertension, and cardiac dysfunction – A comprehensive review." Food Science & Nutrition (2024). PMC11077248.
• Imran M, et al. "Therapeutic application of carvacrol: A comprehensive review." Food Science & Nutrition (2022). PMC9632228.
• Zengin H and Baysal AH. "Antimicrobial Potential of Carvacrol against Uropathogenic Escherichia coli via Membrane Disruption, Depolarization, and Reactive Oxygen Species Generation." Frontiers in Microbiology (2017). PMC5724232.
• Wijesundara NM and Rupasinghe HPV. "Carvacrol exhibits rapid bactericidal activity against Streptococcus pyogenes through cell membrane damage." Scientific Reports (2021). PMC7811018.
• Parnas M, et al. "Carvacrol is a novel inhibitor of Drosophila TRPL and mammalian TRPM7 channels." Cell Calcium (2009). PMC2680423.
• Almanaitytė M, et al. "Effect of Carvacrol, TRP Channels Modulator, on Cardiac Electrical Activity." BioMed Research International (2020). PMC7166271.
• Singh J, Luqman S, Meena A. "Carvacrol as a Prospective Regulator of Cancer Targets/Signalling Pathways." Current Molecular Pharmacology (2023). PubMed PMID 35792130.
• Juhász ML, et al. "Antitumor Effects of Carvacrol and Thymol: A Systematic Review." Cancers (2021). PMC8293693.
• Chaachouay N and Zidane L. "Neuroprotective effects of carvacrol against Alzheimer's disease and other neurodegenerative diseases: A review." Neuroprotection (2022). PMC9121261.
• Andrianova NV, et al. "Neuroprotective Potential and Underlying Pharmacological Mechanism of Carvacrol for Alzheimer's and Parkinson's Diseases." Pharmaceuticals (2023). PMC10324337.
• Al-Snafi AE, et al. "Neuroprotective potential of carvacrol: restoration of oxidative balance and mitigation of brain injury markers in isoproterenol-induced rats." Metabolic Brain Disease (2025). PMC12102131.
• Khazdair MR, et al. "Experimental and clinical evidence on the effect of carvacrol on respiratory, allergic, and immunologic disorders: A comprehensive review." BioFactors (2022). PubMed PMID 35555834.
• Ghorani V, et al. "Safety and tolerability of carvacrol in healthy subjects: a phase I clinical study." Drug and Chemical Toxicology (2021). Vol 44, No 2.
• Mooyottu S, et al. "Protective Effect of Carvacrol against Gut Dysbiosis and Clostridium difficile Associated Disease in a Mouse Model." Frontiers in Microbiology (2017). PMC5399026.
• Upadhyay A, et al. "The Natural Antimicrobial Carvacrol Inhibits Campylobacter jejuni Motility and Infection of Epithelial Cells." PLOS ONE (2012). PMC3458047.
• Rodrigues DB, et al. "Carvacrol Reduces Virulence Traits in Meyerozyma guilliermondii and Candida dubliniensis and Enhances Galleria mellonella Survival During Candidozyma auris Infection." Journal of Fungi (2025). PMC12843738.
• Ridaoui H, et al. "Carvacrol and Thymol Content Affects the Antioxidant and Antibacterial Activity of Origanum compactum and Thymus zygis Essential Oils." Antibiotics (2024). PMC10885931.
• Al-Sayed HM, et al. "Targeting Gastrointestinal Cancers with Carvacrol: Mechanistic Insights and Therapeutic Potential." Molecules (2025). PMC12190638.
• Noman M, et al. "Thymol and Carvacrol: Molecular Mechanisms, Therapeutic Potential, and Synergy With Conventional Therapies in Cancer Management." Food Science & Nutrition (2025).
• Wikipedia. "Carvacrol." (Accessed 2024).